Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania. more
Time Frame | ANVS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -17.7% | -2.12% | -3% |
1-Month Return | -33.18% | -3.42% | -0.73% |
3-Month Return | -48.41% | -11.13% | 2.87% |
6-Month Return | -27.53% | -5.74% | 7.17% |
1-Year Return | -59.35% | 3.97% | 25.31% |
3-Year Return | -78.76% | 1.05% | 28.38% |
5-Year Return | -54.43% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 870.55K | 5.48M | 14.50M | 25.51M | 45.04M | [{"date":"2019-12-31","value":1.93,"profit":true},{"date":"2020-12-31","value":12.17,"profit":true},{"date":"2021-12-31","value":32.2,"profit":true},{"date":"2022-12-31","value":56.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (1.61M) | (6.64M) | (14.54M) | (25.51M) | (45.04M) | [{"date":"2019-12-31","value":-160562200,"profit":false},{"date":"2020-12-31","value":-664022100,"profit":false},{"date":"2021-12-31","value":-1453722100,"profit":false},{"date":"2022-12-31","value":-2551127900,"profit":false},{"date":"2023-12-31","value":-4503501100,"profit":false}] |
Total Non-Operating Income/Expense | 573.71K | 1.23M | 63.42K | 365.42K | (10.49M) | [{"date":"2019-12-31","value":46.82,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":5.18,"profit":true},{"date":"2022-12-31","value":29.82,"profit":true},{"date":"2023-12-31","value":-856.32,"profit":false}] |
Pre-Tax Income | (990.98K) | (5.46M) | (14.49M) | (25.33M) | (56.20M) | [{"date":"2019-12-31","value":-99098000,"profit":false},{"date":"2020-12-31","value":-546204700,"profit":false},{"date":"2021-12-31","value":-1448713200,"profit":false},{"date":"2022-12-31","value":-2532856700,"profit":false},{"date":"2023-12-31","value":-5620431300,"profit":false}] |
Income Taxes | (694.14K) | (1.20M) | (50.09K) | (182.71K) | (45.03K) | [{"date":"2019-12-31","value":-69414200,"profit":false},{"date":"2020-12-31","value":-120467400,"profit":false},{"date":"2021-12-31","value":-5008900,"profit":false},{"date":"2022-12-31","value":-18271200,"profit":false},{"date":"2023-12-31","value":-4503500,"profit":false}] |
Income After Taxes | (296.84K) | (4.26M) | (14.44M) | (25.15M) | (56.16M) | [{"date":"2019-12-31","value":-29683800,"profit":false},{"date":"2020-12-31","value":-425737300,"profit":false},{"date":"2021-12-31","value":-1443704300,"profit":false},{"date":"2022-12-31","value":-2514585500,"profit":false},{"date":"2023-12-31","value":-5615927800,"profit":false}] |
Income From Continuous Operations | (990.98K) | (5.46M) | (14.49M) | (25.33M) | (41.72M) | [{"date":"2019-12-31","value":-99098000,"profit":false},{"date":"2020-12-31","value":-546204700,"profit":false},{"date":"2021-12-31","value":-1448713200,"profit":false},{"date":"2022-12-31","value":-2532856700,"profit":false},{"date":"2023-12-31","value":-4171708600,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (296.84K) | (4.26M) | (14.44M) | (25.15M) | (56.20M) | [{"date":"2019-12-31","value":-29683800,"profit":false},{"date":"2020-12-31","value":-425737300,"profit":false},{"date":"2021-12-31","value":-1443704300,"profit":false},{"date":"2022-12-31","value":-2514585500,"profit":false},{"date":"2023-12-31","value":-5620431300,"profit":false}] |
EPS (Diluted) | (0.10) | (0.84) | (1.90) | (3.77) | (6.13) | [{"date":"2019-12-31","value":-10,"profit":false},{"date":"2020-12-31","value":-84,"profit":false},{"date":"2021-12-31","value":-190,"profit":false},{"date":"2022-12-31","value":-377,"profit":false},{"date":"2023-12-31","value":-613,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ANVS | |
---|---|
Cash Ratio | 2.34 |
Current Ratio | 2.66 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANVS | |
---|---|
ROA (LTM) | -154.58% |
ROE (LTM) | -596.70% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANVS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.51 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.49 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANVS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 8.54 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Annovis Bio Inc (ANVS) share price today is $4.37
Yes, Indians can buy shares of Annovis Bio Inc (ANVS) on Vested. To buy Annovis Bio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANVS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Annovis Bio Inc (ANVS) via the Vested app. You can start investing in Annovis Bio Inc (ANVS) with a minimum investment of $1.
You can invest in shares of Annovis Bio Inc (ANVS) via Vested in three simple steps:
The 52-week high price of Annovis Bio Inc (ANVS) is $22.49. The 52-week low price of Annovis Bio Inc (ANVS) is $4.34.
The price-to-earnings (P/E) ratio of Annovis Bio Inc (ANVS) is
The price-to-book (P/B) ratio of Annovis Bio Inc (ANVS) is 8.54
The dividend yield of Annovis Bio Inc (ANVS) is 0.00%
The market capitalization of Annovis Bio Inc (ANVS) is $60.71M
The stock symbol (or ticker) of Annovis Bio Inc is ANVS